Primary aldosteronism: Clinical lateralization and costs

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 10, 2012, Pages 3450-3452

  Funder, John W ^a  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANTIHYPERTENSIVE AGENT; DIURETIC AGENT; HYDROCORTISONE; POTASSIUM; RENIN; SPIRONOLACTONE;

ACCURACY; ADRENAL TUMOR; ADRENAL VENOUS SAMPLING; ADRENALECTOMY; ALDOSTERONE RELEASE; BLOOD ANALYSIS; BLOOD PRESSURE REGULATION; DIAGNOSTIC VALUE; EDITORIAL; EVIDENCE BASED MEDICINE; FALSE POSITIVE RESULT; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEALTH CARE ACCESS; HEALTH CARE COST; HUMAN; HYPERTENSION; LAPAROSCOPIC SURGERY; MEDICAL SOCIETY; POTASSIUM BLOOD LEVEL; PRACTICE GUIDELINE; PREDICTION; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; SCREENING TEST; TUMOR VOLUME;

ADRENAL CORTEX; ALDOSTERONE; DIAGNOSTIC TECHNIQUES, ENDOCRINE; FEMALE; HUMANS; HYPERALDOSTERONISM; MALE;

EID: 84867266654     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3046     Document Type: Editorial

References (9)

1. Küpers EM, Amar L, Raynaud A, Plouin P-F, Steichen O 2012 A clinical prediction score to diagnose unilateral primary aldosteronism. J Clin Endocrinol Metab 97:3530-3537
2. Kaplan NM 2012 Primary aldosteronism: evidence against a second epidemic. J Hypertens
3. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ 2005 Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45:1243-1248 (Pubitemid 40523144)
4. Hannemann A, Wallaschofski H 2012 Prevalence of primary aldosteronism in patients cohorts and in population-based studies - a review of the current literature. Horm Metab Res 44:157-162
5. Fischer E, Beuschlein F, Bidlingmaier M, Reincke M 2011 Commentary on the Endocrine Society Practice Guidelines: consequences on adjustment of antihypertensive medication in screening or primary aldosteronism. Rev Endocr Metab Disord 12:43-48
6. Levy DG, Rocha R, Funder JW 2004 Distinguishing the antihypertensive and electrolyte effects of eplerenone. J Clin Endocrinol Metab 89:2736-2740 (Pubitemid 38766358)
7. Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, Patni R, Beckerman B 2006 Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 1:940-951
8. Calhoun DA, White WB 2008 Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens 2:462-468
9. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young Jr WF, Montori VM 2008 Case detection, diagnosis and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93:3266-3281